- Home
- All Stock List
- NSE
- Orchid Pharma Ltd Share Price
782.30
6.35 (0.82%)
-
Underperforms Index
-26.53%
Return (1Y)
Underperformed Nifty 50 by 34.97%
-
More Volatile
3.39%
Standard Deviation (1Y)
Higher than Nifty 50 by 2.45%
-
Not so consistent
6/12
Months
underperformed Nifty 50
-
AxisDirect View
No View
1,997
684
News & Announcements
-
Orchid Pharma continues to be under rating watch with developing implications
07 - Mar - 2025 12:00 | 45 days ago
Orchid Pharma announced that CARE has continued the rating CARE A-/ CARE A2 while maintaining a rating watch with developing implications for bank facilities availed by the company.
Powered by Capital Market - Live News
-
Orchid Pharma announced the successful completion of a surprise U.S. Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility. This successful inspection maintains Orchid Pharma's distinguished position as India's only USFDA-approved facility for Sterile Cephalosporins. It reaffirms Orchid Pharma's compliance with USFDA regulatory standards, reinforcing the company's commitment to quality and excellence in pharmaceutical manufacturing.
The Alathur facility specializes in the production of Cephalosporin antibiotics, a critical class of life-saving drugs. Orchid Pharma remains committed to maintaining the highest standards in pharmaceutical manufacturing to ensure continuous supply to the U.S. and global markets.
Additionally, the Alathur API facility has also secured the renewal of its EU Good Manufacturing Practice (GMP) certificate following a successful inspection. This further validates the facility's compliance with European regulatory requirements and its capability to serve global markets.
Powered by Capital Market - Live News
-
Orchid Pharma consolidated net profit declines 29.39% in the December 2024 quarter
12 - Feb - 2025 12:00 | 68 days ago
Net profit of Orchid Pharma declined 29.39% to Rs 20.78 crore in the quarter ended December 2024 as against Rs 29.43 crore during the previous quarter ended December 2023. Sales declined 1.47% to Rs 217.34 crore in the quarter ended December 2024 as against Rs 220.59 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 217.34 220.59 -1 OPM % 12.13 16.04 - PBDT 31.06 39.46 -21 PBT 22.45 30.19 -26 NP 20.78 29.43 -29 Powered by Capital Market - Live News
-
Orchid Pharma announced the successful completion of a surprise U.S. Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility. This successful inspection maintains Orchid Pharma's distinguished position as India's only USFDA-approved facility for Sterile Cephalosporins. It reaffirms Orchid Pharma's compliance with USFDA regulatory standards, reinforcing the company's commitment to quality and excellence in pharmaceutical manufacturing.
The Alathur facility specializes in the production of Cephalosporin antibiotics, a critical class of life-saving drugs. Orchid Pharma remains committed to maintaining the highest standards in pharmaceutical manufacturing to ensure continuous supply to the U.S. and global markets.
Additionally, the Alathur API facility has also secured the renewal of its EU Good Manufacturing Practice (GMP) certificate following a successful inspection. This further validates the facility's compliance with European regulatory requirements and its capability to serve global markets.
Powered by Capital Market - Live News
-
Orchid Pharma consolidated net profit declines 29.39% in the December 2024 quarter
12 - Feb - 2025 12:00 | 68 days ago
Net profit of Orchid Pharma declined 29.39% to Rs 20.78 crore in the quarter ended December 2024 as against Rs 29.43 crore during the previous quarter ended December 2023. Sales declined 1.47% to Rs 217.34 crore in the quarter ended December 2024 as against Rs 220.59 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 217.34 220.59 -1 OPM % 12.13 16.04 - PBDT 31.06 39.46 -21 PBT 22.45 30.19 -26 NP 20.78 29.43 -29 Powered by Capital Market - Live News
-
Orchid Pharma to announce Quarterly Result
73 days ago
-
Orchid Pharma continues to be under rating watch with developing implications
07 - Mar - 2025 12:00 | 45 days ago
Orchid Pharma announced that CARE has continued the rating CARE A-/ CARE A2 while maintaining a rating watch with developing implications for bank facilities availed by the company.
Powered by Capital Market - Live News
-
Orchid Pharma announced the successful completion of a surprise U.S. Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility. This successful inspection maintains Orchid Pharma's distinguished position as India's only USFDA-approved facility for Sterile Cephalosporins. It reaffirms Orchid Pharma's compliance with USFDA regulatory standards, reinforcing the company's commitment to quality and excellence in pharmaceutical manufacturing.
The Alathur facility specializes in the production of Cephalosporin antibiotics, a critical class of life-saving drugs. Orchid Pharma remains committed to maintaining the highest standards in pharmaceutical manufacturing to ensure continuous supply to the U.S. and global markets.
Additionally, the Alathur API facility has also secured the renewal of its EU Good Manufacturing Practice (GMP) certificate following a successful inspection. This further validates the facility's compliance with European regulatory requirements and its capability to serve global markets.
Powered by Capital Market - Live News
-
Orchid Pharma consolidated net profit declines 29.39% in the December 2024 quarter
12 - Feb - 2025 12:00 | 68 days ago
Net profit of Orchid Pharma declined 29.39% to Rs 20.78 crore in the quarter ended December 2024 as against Rs 29.43 crore during the previous quarter ended December 2023. Sales declined 1.47% to Rs 217.34 crore in the quarter ended December 2024 as against Rs 220.59 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 217.34 220.59 -1 OPM % 12.13 16.04 - PBDT 31.06 39.46 -21 PBT 22.45 30.19 -26 NP 20.78 29.43 -29 Powered by Capital Market - Live News
-
Orchid Pharma to announce Quarterly Result
73 days ago
-
Orchid Pharma continues to be under rating watch with developing implications
07 - Mar - 2025 12:00 | 45 days ago
Orchid Pharma announced that CARE has continued the rating CARE A-/ CARE A2 while maintaining a rating watch with developing implications for bank facilities availed by the company.
Powered by Capital Market - Live News
-
Orchid Pharma announced the successful completion of a surprise U.S. Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility. This successful inspection maintains Orchid Pharma's distinguished position as India's only USFDA-approved facility for Sterile Cephalosporins. It reaffirms Orchid Pharma's compliance with USFDA regulatory standards, reinforcing the company's commitment to quality and excellence in pharmaceutical manufacturing.
The Alathur facility specializes in the production of Cephalosporin antibiotics, a critical class of life-saving drugs. Orchid Pharma remains committed to maintaining the highest standards in pharmaceutical manufacturing to ensure continuous supply to the U.S. and global markets.
Additionally, the Alathur API facility has also secured the renewal of its EU Good Manufacturing Practice (GMP) certificate following a successful inspection. This further validates the facility's compliance with European regulatory requirements and its capability to serve global markets.
Powered by Capital Market - Live News
-
Orchid Pharma consolidated net profit declines 29.39% in the December 2024 quarter
12 - Feb - 2025 12:00 | 68 days ago
Net profit of Orchid Pharma declined 29.39% to Rs 20.78 crore in the quarter ended December 2024 as against Rs 29.43 crore during the previous quarter ended December 2023. Sales declined 1.47% to Rs 217.34 crore in the quarter ended December 2024 as against Rs 220.59 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 217.34 220.59 -1 OPM % 12.13 16.04 - PBDT 31.06 39.46 -21 PBT 22.45 30.19 -26 NP 20.78 29.43 -29 Powered by Capital Market - Live News
-
Orchid Pharma announced the successful completion of a surprise U.S. Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility. This successful inspection maintains Orchid Pharma's distinguished position as India's only USFDA-approved facility for Sterile Cephalosporins. It reaffirms Orchid Pharma's compliance with USFDA regulatory standards, reinforcing the company's commitment to quality and excellence in pharmaceutical manufacturing.
The Alathur facility specializes in the production of Cephalosporin antibiotics, a critical class of life-saving drugs. Orchid Pharma remains committed to maintaining the highest standards in pharmaceutical manufacturing to ensure continuous supply to the U.S. and global markets.
Additionally, the Alathur API facility has also secured the renewal of its EU Good Manufacturing Practice (GMP) certificate following a successful inspection. This further validates the facility's compliance with European regulatory requirements and its capability to serve global markets.
Powered by Capital Market - Live News
-
Orchid Pharma consolidated net profit declines 29.39% in the December 2024 quarter
12 - Feb - 2025 12:00 | 68 days ago
Net profit of Orchid Pharma declined 29.39% to Rs 20.78 crore in the quarter ended December 2024 as against Rs 29.43 crore during the previous quarter ended December 2023. Sales declined 1.47% to Rs 217.34 crore in the quarter ended December 2024 as against Rs 220.59 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 217.34 220.59 -1 OPM % 12.13 16.04 - PBDT 31.06 39.46 -21 PBT 22.45 30.19 -26 NP 20.78 29.43 -29 Powered by Capital Market - Live News
-
Orchid Pharma to announce Quarterly Result
73 days ago
Stock Trivia
Orchid Pharma Ltd has been the 3rd best in 5 years performance among stocks in Pharmaceuticals Sector
FII shareholding in Orchid Pharma Ltd has decreased by -38.87% since past 1 Year
Orchid Pharma Ltd has been the 3rd best in 5 years performance among stocks in Pharmaceuticals Sector
FII shareholding in Orchid Pharma Ltd has increased by 30.66% since past 3 Months
MF shareholding in Orchid Pharma Ltd has increased by 4.02% since past 3 Months
FII shareholding in Orchid Pharma Ltd has decreased by -38.87% since past 1 Year
Orchid Pharma Ltd has been the 3rd best in 5 years performance among stocks in Pharmaceuticals Sector
FII shareholding in Orchid Pharma Ltd has decreased by -38.87% since past 1 Year
